Short answer
Adaptive Biotechnologies Corp (ADPT) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $72M (up 21.5% year over year) with net income of −$40M.
Q2 2026 key financials · XBRL
- Revenue
- $72M
- +21.5% YoY · +1.0% QoQ
- Net income
- −$40M
- −55.3% YoY · −98.6% QoQ
- Operating margin
- -22.0%
- EPS (diluted)
- −$0.25
- −47.1% YoY · −92.3% QoQ
Source: XBRL data from the Adaptive Biotechnologies Corp (ADPT) Q2 2026 10-Q on SEC EDGAR. USD.
Adaptive Biotechnologies Corp Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- $345.0 million Notes issued in June 2026, increasing leverage and cash-flow demands
- Notes due 2031 may require cash repurchase upon fundamental change or cash payments at conversion
- Immune Medicine separation creates execution risk, including potential capital and personnel access constraints
- Notes conversion could dilute existing shareholders and reduce common-stock value
- Harell platform agreement restricts licensing datasets to platforms other than Harell’s usage-based model
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Adaptive Biotechnologies Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.